Drug Prices
The issue of affordability, including health care affordability, is front and center this year and will be part of this year's congressional and administration discussions, as well as the mid-term elections.
AHA Statement before the House Committee on Energy and Commerce
Health Subcommittee on “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain”
The White House yesterday launched TrumpRx, the direct-to-consumer platform that will serve as a hub to direct cash-paying consumers to drug manufacturers and pharmacies to purchase discounted prescription drugs. The website offers coupons to consumers to purchase drugs at most-…
The Department of Health and Human Services Office of Inspector General Jan. 27 released a bulletin addressing how direct-to-consumer drug programs can sell prescription drugs to patients with federal health care program coverage at lower costs without violating the Anti-Kickback Statute.
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations.
The White House released a health care plan Jan. 15 addressing drug prices, health insurance premiums and price transparency efforts.
Absent any statutory consequences for not completing the OPPS Drug Acquisition Cost Survey (ODACS), it is wrong for CMS to tell hospitals and health systems that they “are to” complete it.
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model, BALANCE, for Medicare Part D and Medicaid beneficiaries.
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models.
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid by other developed nations.